Premium
Cytokeratin immunoreactivity in gliomas
Author(s) -
NG HK.,
LO S. T. H.
Publication year - 1989
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1989.tb02164.x
Subject(s) - cytokeratin , pathology , anaplastic astrocytoma , glial fibrillary acidic protein , immunostaining , immunohistochemistry , astrocytoma , glioma , polyclonal antibodies , biology , antibody , medicine , cancer research , immunology
Monoclonal antibodies (AE1/3, CAM 5.2 and PKK‐1) and polyclonal antisera against the cytokeratin proteins were reacted with a range of astrocytic tumours, oligodendrogliomas and ependymomas. Seven of 12 cases (58%) of glioblastoma multiforme, five of eight (63%) anaplastic astrocytomas and two of five (40%) well‐differentiated astrocytomas were immunoreactive with AE1/3 but not with the other anti‐cytokeratin antibodies. In oligodendrogliomas, AEl/3 stained isolated astrocyte‐like cells as well as scattered neoplastic oligodendrocytes in four of eight cases (50%) cases. Four ependymomas were negative for all cytokeratin markers examined. The immunostaining of astrocytomas and oligodendrogliomas with AE1/3 might represent co‐expression of cytokeratin with glial fibrillary acidic protein by gliomas and calls for caution in the use of these antibodies in the differential diagnosis between gliomas and carcinomas.